Tatva Chintan Pharma Chem Limited (TATVA) AI Stock Analysis

• Market Cap: ₹32.76B
• Dividend Yield: 0.07%
• Average Volume (3M): 12.52K
• Price to Earnings (P/E): 184.7
• Beta (1Y): 1.01
• Revenue Growth: 16.88%
• EPS Growth: 0.69%
• Country: IN
• Employees: 689
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 4.35
• Shares Outstanding: 23,392,056
• 10 Day Avg. Volume: 25,333
• 30 Day Avg. Volume: 12,516
• PEG Ratio: -3.55
• Price to Book (P/B): 2.24
• Price to Sales (P/S): 4.33
• P/FCF Ratio: -32.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: ₹1,372.00 ▼(-2.04% Downside)

Tatva Chintan Pharma Chem Limited's overall stock score is driven by strong technical momentum, despite high valuation concerns. The financial performance is mixed, with a solid balance sheet but challenges in revenue growth and cash flow management. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Strong Balance Sheet

A strong balance sheet with low leverage provides financial stability and flexibility for future investments, supporting long-term growth.

Operational Efficiency

Positive EBIT and EBITDA margins indicate effective cost management and operational efficiency, which are crucial for sustaining profitability.

Revenue Model

A diversified revenue model with specialized products and long-term contracts ensures steady income and resilience against market volatility.

Negative Factors

Revenue Decline

A decline in revenue and net profit margin indicates challenges in market demand or pricing power, potentially impacting future growth.

Cash Flow Challenges

Persistent negative free cash flow due to high capital expenditures could strain liquidity, requiring strategic cash management to sustain operations.

Profitability Volatility

Volatile profitability and a sharp decrease in net profit margin suggest challenges in cost control and pricing strategy, affecting long-term stability.

Tatva Chintan Pharma Chem Limited Business Overview & Revenue Model

Company Description

Tatva Chintan Pharma Chem Limited manufactures and sells specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; and pharmaceutical APIs, agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. It also provides quaternary compounds and quats, and bulk drugs, as well as trading of specialty chemicals. It serves various industries, including the automotive, petroleum, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. The company also exports its products to approximately 25 countries. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.

How the Company Makes Money

Tatva Chintan Pharma Chem Limited generates revenue through the production and sale of a wide array of fine chemicals and intermediates, primarily targeting the pharmaceutical and agrochemical sectors. Its revenue model hinges on the manufacturing of specialized chemical products tailored to the needs of its clients, which include major pharmaceutical companies. Key revenue streams include the sale of APIs, pharmaceutical intermediates, and specialty chemicals that are sold both domestically and internationally. The company also benefits from long-term contracts with major clients, which provides a steady income flow. Additionally, TATVA invests in research and development to create new products and improve existing ones, enhancing its market competitiveness and driving sales growth. Strategic partnerships with other industries and collaborations for product development further contribute to its revenue generation.

Tatva Chintan Pharma Chem Limited Financial Statement Overview

Summary

Tatva Chintan Pharma Chem Limited shows a mixed financial performance. The income statement indicates inconsistent revenue growth and declining profit margins, though operational efficiency remains. The balance sheet is strong with low leverage, but asset utilization could improve. Cash flow challenges due to high capital expenditures suggest a need for strategic cash management.

Income Statement

Tatva Chintan Pharma Chem Limited exhibits a mixed performance in its income statement. The company has shown inconsistent revenue growth with a decline in revenue from 2024 to 2025, which may raise concerns. Gross Profit Margin has been strong historically but has recently declined, indicating cost pressures. The Net Profit Margin has been volatile, showing a sharp decrease in 2025, which suggests challenges in maintaining profitability. Despite these fluctuations, the company maintains positive EBIT and EBITDA margins, which reflect underlying operational efficiency.

Balance Sheet

The balance sheet of Tatva Chintan Pharma Chem Limited is solid, with a strong equity position. The Debt-to-Equity Ratio is low, indicating conservative leverage and financial stability. The Equity Ratio is robust, reflecting a strong capital base. However, the Return on Equity has decreased over time, suggesting potential inefficiencies in generating returns from equity capital. Overall, the company is financially stable, but there are areas for improvement in asset utilization.

Cash Flow

The cash flow statement reflects challenges with negative free cash flow across the years, primarily due to high capital expenditure, which may indicate investment for future growth but affects current liquidity. Operating Cash Flow to Net Income Ratio is positive, showing that operational cash generation is supporting net income. However, the Free Cash Flow to Net Income Ratio is negative, highlighting the pressure from capital outlays. The negative Free Cash Flow Growth Rate suggests a need for careful cash management moving forward.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.94B	3.83B	3.94B	4.24B	4.34B	3.00B
Gross Profit	1.94B	1.84B	2.11B	1.91B	2.32B	1.43B
EBITDA	390.31M	342.13M	689.34M	676.30M	1.08B	666.37M
Net Income	71.55M	57.13M	303.54M	454.87M	958.74M	522.62M
Balance Sheet
Total Assets	0.00	8.36B	8.19B	7.56B	6.58B	3.15B
Cash, Cash Equivalents and Short-Term Investments	140.96M	117.01M	456.68M	412.15M	638.19M	53.24M
Total Debt	0.00	363.88M	142.71M	1.70B	1.20B	902.48M
Total Liabilities	-7.39B	974.25M	816.36M	2.42B	1.85B	1.49B
Stockholders Equity	7.39B	7.39B	7.37B	5.15B	4.73B	1.66B
Cash Flow
Free Cash Flow	0.00	-516.01M	-304.71M	-1.75B	-687.79M	33.49M
Operating Cash Flow	0.00	246.71M	980.44M	277.83M	203.78M	243.19M
Investing Cash Flow	0.00	-652.54M	-1.21B	-1.01B	-1.97B	-207.02M
Financing Cash Flow	0.00	165.66M	305.19M	377.95M	2.35B	-44.80M

Tatva Chintan Pharma Chem Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1400.60
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:TATVA, the sentiment is Neutral. The current price of 1400.6 is below the 20-day moving average (MA) of 1430.27, below the 50-day MA of 1410.12, and above the 200-day MA of 1035.27, indicating a neutral trend. The MACD of -4.32 indicates Positive momentum. The RSI at 43.97 is Neutral, neither overbought nor oversold. The STOCH value of 32.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:TATVA.

Tatva Chintan Pharma Chem Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FCL	75 Outperform	₹27.50B	28.04	―	0.67%	-10.12%	-22.38%
TATVA	64 Neutral	₹32.76B	184.73	―	0.07%	16.88%	0.69%
PUNJABCHEM	64 Neutral	₹15.33B	29.31	―	0.24%	10.70%	32.65%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
IOLCP	60 Neutral	₹24.14B	20.84	―	0.97%	5.74%	16.06%
KIRIINDUS	60 Neutral	₹34.16B	26.36	―	―	-22.04%	-58.81%
YASHO	52 Neutral	₹17.32B	136.78	―	0.03%	11.74%	-64.13%

Tatva Chintan Pharma Chem Limited Corporate Events

Tatva Chintan Pharma Chem Schedules Investor Meeting with Sequent Investments

Tatva Chintan Pharma Chem Limited has announced a scheduled virtual meeting with Sequent Investments on November 26, 2025. This meeting is part of the company’s ongoing investor relations efforts, where they will discuss publicly available information, ensuring no confidential or unpublished price-sensitive information is shared. This initiative reflects the company’s commitment to transparency and maintaining strong communication with its stakeholders.

Tatva Chintan Pharma Chem Clarifies Share Price Movement Amid Market Conditions

Tatva Chintan Pharma Chem Limited addressed recent price movements in its shares, attributing them to market conditions rather than undisclosed material events. The company assured stakeholders of its compliance with regulatory disclosure requirements, emphasizing that all significant information affecting its operations and share price has been transparently communicated.